Brief: Aptinyx Announces Recommencement Of Phase 2 Study Of Nyx-2925 In Patients With Painful Diabetic Peripheral Neuropathy
04/01/2021 12:57
Jan 4 (Reuters) - Aptinyx Inc APTX.O :
* APTINYX ANNOUNCES RECOMMENCEMENT OF PHASE 2 STUDY OF
NYX-2925 IN
PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY
* APTINYX INC - STUDY HAS RESUMED FOLLOWING SUSPENSION OF
ENROLLMENT DUE TO ESCALATION OF COVID-19 PANDEMIC
* APTINYX INC - DATA READOUTS FOR NYX-2925 STUDIES IN BOTH
PAINFUL
DPN AND FIBROMYALGIA EXPECTED IN 1H 2022
Source text for Eikon: ID:nBw7SrzzKa
Further company coverage: APTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptinyx
See all newsBrief: Aptinyx Gets Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Aptinyx Inc reports On May 4, Board Deemed It In Best Interests Of Co And Its Stockholders That Co Be Dissolved
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Inc Reports Quarterly Loss Per Share Of $0.18
Aptinyx Inc expected to post a loss of 19 cents a share - Earnings Preview